BLOCKADE OF THE INTERLEUKIN (IL)-2/IL-2 RECEPTOR PATHWAY WITH A MONOCLONAL ANTI-IL-2 RECEPTOR ANTIBODY (BT563) DOES NOT PREVENT THE DEVELOPMENT OF ACUTE HEART ALLOGRAFT REJECTION IN HUMANS
- 1 February 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (3) , 405-410
- https://doi.org/10.1097/00007890-199802150-00020
Abstract
Anti-interleukin (IL)-2 receptor (IL-2R) antibodies have been used as rejection prophylaxis after organ transplantation. Despite this induction treatment, acute rejections may occur. We wondered whether these rejections developed via the IL-2/IL-2R pathway. In a prospective trial using BT563, a murine IgG1 anti-IL-2R antibody, for rejection prophylaxis after heart transplantation, 20 patients were treated in combination with cyclosporine from the day of transplantation(group A). As a control group, 31 patients were also treated with BT563, but in these patients, cyclosporine treatment was initiated on day 3 (group B). Three patients from group A and two patients from group B died in the first postoperative month (of causes not related to acute rejection) and were left out of the analysis of rejection incidence. Freedom from acute rejection at 1 week after transplantation in group A (14/17; 82%) was lower than in group B (16/29; 55%), although the difference did not reach statistical significance. There was no difference in either the number of acute rejection episodes at 12 weeks or the required rejection treatments between groups A and B. Infectious complications were evenly distributed in both groups. Immunohistochemistry showed that during acute rejection, in the presence of circulating BT563, IL-2R-bearing cells were present in only one of five rejection biopsies (20%), whereas these cells were often present (6/8, or 75%) in rejections occurring in the absence of BT563. The presence of BT563 was associated with a similar difference in the mRNA expression of IL-2 (2/5 vs. 6/8). Apparently, despite adequate blockade of the IL-2/IL-2R pathway, patients may develop acute rejection, reflecting the redundancy of the cytokine network. The ever-present IL-15 may well be a candidate for overtaking the role of IL-2.Keywords
This publication has 17 references indexed in Scilit:
- A PROSPECTIVE RANDOMIZED TRIAL COMPARING INTERLEUKIN-2 RECEPTOR ANTIBODY VERSUS ANTITHYMOCYTE GLOBULIN AS PART OF A QUADRUPLE IMMUNOSUPPRESSIVE INDUCTION THERAPY FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 1997
- A RANDOMIZED TRIAL COMPARING SAFETY AND EFFICACY OF OKT3 AND A MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) IN THE PREVENTION OF ACUTE REJECTION AFTER HEART TRANSPLANTATIONTransplantation, 1996
- A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MONOCLONAL ANTI-INTERLEUKIN-2 RECEPTOR ANTIBODY (BT563) ADMINISTRATION TO PREVENT ACUTE REJECTION AFTER KIDNEY TRANSPLANTATIONTransplantation, 1995
- PREVENTION OF ACUTE REJECTION EPISODES WITH AN ANTI-INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODYTransplantation, 1994
- PREVENTION OF ACUTE REJECTION EPISODES WITH AN ANTI-INTERLEUKIN 2 RECEPTOR MONOCLONAL ANTIBODYTransplantation, 1994
- A RANDOMIZED CLINICAL TRIAL OF INDUCTION THERAPY WITH OKT3 IN KIDNEY TRANSPLANTATIONTransplantation, 1993
- A RANDOMIZED PROSPECTIVE TRIAL OF ANTI-TAC MONOCLONAL ANTIBODY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1991
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- Randomized Controlled Trial of a Monoclonal Antibody against the Interleukin-2 Receptor (33B3.1) as Compared with Rabbit Antithymocyte Globulin for Prophylaxis against Rejection of Renal AllograftsNew England Journal of Medicine, 1990
- A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal TransplantsNew England Journal of Medicine, 1985